Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button

Home > Press > Nanogen Extends Celera License Agreement for Additional IVD Products

Abstract:
Nanogen, Inc. (Nasdaq:NGEN), developer of molecular-biology and rapid diagnostic products, announced today that Celera Corporation has extended its license agreement of Nanogen's patent portfolio in molecular biology to develop additional diagnostic products.

Nanogen Extends Celera License Agreement for Additional IVD Products

San Diego, CA | Posted on October 23rd, 2008

Celera Corporation will use Nanogen's Minor Groove Binder (MGB) technology to develop in vitro diagnostic products for cardiovascular and oncological applications. This is an expansion of the original license agreement, signed in 2004, in which Celera licensed the technology for development of a hepatitis C genotyping products for individual patient management, monitoring and treatment. Under the Agreement, Celera Corporation will pay Nanogen an upfront license fee, milestone and anniversary fees throughout development, and a royalty on sales of the diagnostic products.

"The Celera license expands our current license into new and exciting molecular diagnostic applications," said Howard Birnsdorf, Nanogen CEO. "Our MGB technology has been licensed to a number of companies and the expanded field for Celera strongly supports the value of our technology in real-time PCR."

Nanogen's MGB technology is licensed broadly in various fields and is now an integral component in thousands of PCR probe products. Nanogen has more than 35 reagent and kit products that are sold for clinical diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.

####

About Nanogen, Inc.
Nanogen provides innovative, high-quality diagnostic products to clinicians, physicians and researchers worldwide, making it easier to predict, diagnose and, ultimately, help treat disease in a timely fashion. The company's products include molecular diagnostic kits and reagents and kits for rapid, point-of-care diagnostic tests. Nanogen has pioneered research in areas involving nanotechnology, biomarkers, and molecular biology to bring better results to diagnostics and healthcare.

About Celera

Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.celera.com.

For more information, please click here

Contacts:
Nanogen, Inc.
Nicholas Venuto
Chief Financial Officer
858-410-4600
Kelly Gann
Marketing Communications
858-410-4667

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists find a way of acquiring graphene-like films from salts to boost nanoelectronics: Physicists use supercomputers to find a way of making 'imitation graphene' from salt July 30th, 2016

Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016

New method for making green LEDs enhances their efficiency and brightness July 30th, 2016

A new type of quantum bits July 29th, 2016

Nanomedicine

Scientists change properties of zeolites to improve hemodialysis July 29th, 2016

Pixel-array quantum cascade detector paves the way for portable thermal imaging devices: Research team from TU-Wien Center for Micro- and Nanostructures have developed a new 'cooler' sensing instrument thereby increasing energy-efficiency and enhancing mobility for diagnostic tes July 28th, 2016

Starpharma initiates new DEP™ drug delivery program with AstraZeneca July 27th, 2016

Scientists test nanoparticle drug delivery in dogs with osteosarcoma July 26th, 2016

Announcements

Scientists find a way of acquiring graphene-like films from salts to boost nanoelectronics: Physicists use supercomputers to find a way of making 'imitation graphene' from salt July 30th, 2016

Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016

New method for making green LEDs enhances their efficiency and brightness July 30th, 2016

A new type of quantum bits July 29th, 2016

Patents/IP/Tech Transfer/Licensing

Starpharma initiates new DEP™ drug delivery program with AstraZeneca July 27th, 2016

Integration of novel materials with silicon chips makes new 'smart' devices possible July 25th, 2016

Research team led by NUS scientists develop plastic flexible magnetic memory device: Novel technique to implant high-performance magnetic memory chip on a flexible plastic surface without compromising performance July 21st, 2016

New nanoscale technologies could revolutionize microscopes, study of disease July 20th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic